Sandoz teams up with World Child Cancer to “even the odds” for children worldwide

Holzkirchen, February 15, 2016 – Sandoz, together with leading global charity World Child Cancer (WCC), is pleased to announce a new health initiative in the Philippines, aimed at improving the standard of care for children suffering from cancer.

Cancer survival rates for children in the Philippines are less than 20%, compared to an average of 80% in developed countries. The goal of the new partnership, further details of which will be announced next month, is to help “even the odds” by supporting the development of specialist treatment centers in the island region …

/by

Sandoz teams up with World Child Cancer to “even the odds” for children worldwide

Holzkirchen, February 15, 2016 – Sandoz, together with leading global charity World Child Cancer (WCC), is pleased to announce a new health initiative in the Philippines, aimed at improving the standard of care for children suffering from cancer.

Cancer survival rates for children in the Philippines are less than 20%, compared to an average of 80% in developed countries. The goal of the new partnership, further details of which will be announced next month, is to help “even the odds” by supporting the development of specialist treatment centers in the island region …

/by

Sandoz strengthens its biosimilars portfolio with acquisition of Pfizer’s biosimilar infliximab in EEA

  • Sandoz acquires rights to PF-06438179 (biosimilar infliximab) in the European Economic Area (EEA)*

  • Sandoz plans to complete Phase III development program and file for registration in the EU

  • Deal strengthens Novartis immunology portfolio which includes investigational biosimilars adalimumab, etanercept and rituximab

Holzkirchen, 12 February, 2016 – Sandoz, a Novartis company and a global leader in biosimilars, announced today that it has acquired from Pfizer the rights for the development and commercialization of PF- …

/by